Dental Pulp Cells Can Repair Tissues Beyond the Mouth

Scientists around the world are culturing and testing dental pulp cells in the lab. At CSIRO’s Stem Cell Centre in Australia, for instance, researchers examine cultured stem‑cell samples under high‑resolution microscopes.

In the lab, DPSCs self‑renew and proliferate rapidly. Studies show that when given the right signals, DPSCs will lay down collagen and calcium to form bone or cartilage matrix and even beat and contract like muscle.

Compared with bone‑marrow stem cells, DPSCs often build mineralized (bone) tissue more quickly. In engineered joint grafts they can produce cartilage tissue in vitro. In one animal study, combining human dental pulp cells with a scaffold led to significantly more new bone growth than a scaffold alone.

Such findings give hope that wisdom‑tooth cells could one day aid in healing fractures, repairing jawbones after tumor surgery, or rebuilding degenerated cartilage in arthritic joints. Each year millions of wisdom teeth are removed and usually discarded. In the United States alone an estimated ten million molars are extracted annually.

Tooth Banking and the Future of Personalized Medicine

A growing number of biotech startups and dental clinics now offer “tooth banking” – preserving a patient’s pulp cells for possible future use. The process of collecting dental pulp stem cells begins immediately after the tooth is removed.

The extracted wisdom tooth is placed in a sterile container and transported under cold conditions to a laboratory. There, specialists extract the pulp tissue and typically freeze the stem cells within a day to preserve their viability.

Proponents note that banking one’s own DPSCs eliminates concerns about immune rejection later, and the upfront cost (comparable to cord‑blood banking) could pay off if personalized therapies are needed decades down the line.

Clinics partner with oral surgeons to harvest molars that would otherwise be discarded, turning “trash” into a long‑term biological asset. Early experiments hint at a wide range of potential therapies.

For example, cardiologists have tested injections of dental‑pulp cell secretions in rodents with heart failure, and observed improved cardiac function – suggesting that a patient’s own wisdom‑tooth cells might one day help mend a damaged heart.

In neurological studies, DPSC transplants into Alzheimer’s‑model mice produced measurable improvements in memory and brain pathology.

It can generate dopamine‑producing neurons in culture, and rodent models of Parkinson’s disease showed motor improvements with dental stem cell therapy.

DPSCs appear to secrete a cocktail of growth factors that protect nerves, reduce inflammation and even help clear toxic proteins in the brain. Outside the nervous system, laboratories report that dental pulp cells readily become osteoblast‑like and build bone in 3D scaffolds, making them promising for filling bone defects.

More Work Is Needed to Prove Safety and Efficacy

As the evidence grows, investigators are planning clinical trials of dental pulp therapies. Early stem‑cell implants (using embryonic stem cells) in Parkinson’s patients have already demonstrated that new dopamine neurons can survive and function in humans. Using DPSCs instead could avoid ethical controversies and reduce immune risk.

However, experts caution that more work is needed. Transplanted cells must be shown safe (without forming tumors) and effective in people. Scientists at universities and institutes worldwide – for example at the University of the Basque Country in Spain – continue refining protocols to turn tooth pulp into therapy. “These are easily accessible human stem cells for nerve tissue engineering,” researchers note.

They argue that routinely preserving wisdom teeth now could create a personalized “biobank” of one’s own stem cells, offering future regenerative treatments without the wait for a perfect donor match. Wisdom teeth may have been viewed as nuisances, but modern research is recasting them as biological treasure.

Before tossing those extracted molars, patients might consider the hidden value inside. In the coming years, therapies for bone injuries, neurological diseases or heart disease may indeed spring from the “medical gold” locked in wisdom tooth pulp.

[Source: 1,2]

The post “Medical Gold” From Extracted Wisdom Teeth Are Being Used to Treat a Range of Diseases appeared first on Medical Journal Daily.

The therapy, known as zimislecel, is made from lab-grown islet cells developed from pluripotent stem cells. These engineered cells are designed to replace the insulin-producing beta cells destroyed in people with type 1 diabetes. In the study, the cells were delivered into patients’ livers through the portal vein and began producing insulin naturally.

A Small but Promising Study

The trial, conducted by Vertex Pharmaceuticals, involved 14 participants. All had type 1 diabetes with no measurable C-peptide at baseline, indicating an absence of natural insulin production. Of the 12 individuals who received the complete zimislecel infusion, 10 no longer required insulin a year later.

Each participant showed signs of functioning islet cells and avoided any serious hypoglycemic incidents during the last nine months of follow-up.

The trial results, presented at the 2025 American Diabetes Association conference and published in The New England Journal of Medicine, point to zimislecel as a possible treatment route for patients with difficult-to-manage or advanced type 1 diabetes.

Restoring Natural Insulin Production

Participants in the trial had previously lived with hypoglycemic unawareness, a complication where the body no longer warns of dangerously low blood sugar levels. This can result in sudden fainting, seizures, or even death. Following treatment with a full dose of zimislecel, none of the 12 participants experienced additional episodes of dangerously low blood sugar.

The infusion triggered insulin production within weeks. Patients began reducing their insulin requirements around the three-month mark, with most stopping entirely by month six. All participants spent more than 70 percent of their time in the recommended blood glucose range between 70 and 180 mg/dL.

Amanda Smith described the experience as a return to normalcy. She joined the study after years of managing her blood sugar around the clock. The result, she said, has been “a whole new life,” though she remains on immunosuppressive medication to preserve the function of the transplanted cells.

Managing the Risks of Immune Suppression

To prevent the body from rejecting the implanted cells, all participants were placed on immunosuppressive drugs. While these medications were chosen to avoid corticosteroids, they still carry risks.

Three participants developed neutropenia, a condition that weakens the immune system, and two died during the study’s follow-up period. One death was linked to fungal meningitis, and the other to worsening dementia. Both patients had underlying medical conditions before entering the trial.

Researchers acknowledged these risks and emphasized the importance of long-term monitoring. “We’re still learning what this means over the course of many years,” said Dr. Trevor Reichman, pancreas and islet transplant program director at University Health Network in Toronto and lead author of the study.

Built on Decades of Research

Zimislecel is the result of over two decades of work, beginning with a Harvard lab led by Dr. Doug Melton. Motivated by his children’s diagnoses with type 1 diabetes, Dr. Melton focused his career on transforming stem cells into functioning islet cells. After finding a reliable method, the research was taken forward by Vertex Pharmaceuticals for clinical development.

The trial was limited to patients with severe diabetes who could not manage their condition effectively with current therapies. Enrollment was selective, and some eligible patients declined participation after learning they would need immunosuppressive drugs for life.

A New Option for a High-Risk Group

Dr. Irl Hirsch, a diabetes expert from the University of Washington who was not affiliated with the research, observed that the therapy may serve a critical role for patients at high risk of sudden and severe glucose drops. He added that for patients with well-managed type 1 diabetes, the trade-offs may not be worth the risk until safer long-term data become available.

Zimislecel is not yet approved for public use, and pricing has not been disclosed. Vertex plans to continue testing zimislecel in future studies and aims to submit its findings to the U.S. Food and Drug Administration for review.

For patients like Amanda Smith, the therapy represents a shift in what diabetes care could look like. Though not a cure, zimislecel shows that it may be possible to restore the body’s own insulin production with a single intervention—at least for those who need it most.

[Source]

The post Type 1 Diabetes Patients Off Insulin After a Single Dose of Experimental Manufactured Stem Cells appeared first on Medical Journal Daily.